PMID- 35047521
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220121
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Predictors of a Minimal Clinically Important Difference Following Omalizumab 
      Treatment in Adult Patients With Severe Allergic Asthma.
PG  - 762318
LID - 10.3389/fmed.2021.762318 [doi]
LID - 762318
AB  - Several factors have been found to be predictors of a good response following 
      omalizumab treatment in patients with severe allergic asthma (SAA). However, it 
      remains unclear whether clinical characteristics can predict a minimal clinically 
      important difference (MCID) following omalizumab treatment in this population. 
      Therefore, the aim of this study was to investigate the features associated with 
      an MCID following omalizumab treatment in adult patients with SAA. Of the 124 
      participants enrolled in this retrospective, cross-sectional study, 94, 103, 20 
      and 53 achieved the MCID following treatment with omalizumab and were considered 
      to be responders of exacerbation reduction (no exacerbation during the 1-year 
      follow-up period or >==50% reduction in exacerbations from baseline), oral 
      corticosteroid (OCS) sparing (no use of OCS to control asthma during the study 
      period or a reduction of the monthly OCS maintenance dose to <50% of baseline), 
      lung function (an increase of >==230 ml in the forced expiratory volume in 1 s from 
      baseline) and asthma control (an increase of >==3 points in the asthma control test 
      score from baseline), respectively. Normal weight [<25 vs. >==30 kg/m(2), odds 
      ratio (OR) = 3.86, p = 0.024] was predictive of a responder of reduction in 
      exacerbations following omalizumab treatment while subjects with a blood 
      eosinophil level of <300 cells/muL (<300 vs. >==300 cells/muL, OR = 5.81, p = 0.001) 
      were more likely to exhibit an MCID in OCS sparing. No factor was found to be a 
      predictor of lung function or asthma control. When choosing treatment for adult 
      patients with SAA, our findings may help to select those who may benefit the most 
      from omalizumab treatment.
CI  - Copyright (c) 2022 Huang, Fu, Chan, Chin, Huang, Lai, Wang, Hung, Wu, Hsieh, Wu, 
      Chen and Hsu.
FAU - Huang, Wei-Chang
AU  - Huang WC
AD  - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - College of Medicine, National Chung Hsing University, Taichung, Taiwan.
AD  - Ph.D. Program in Translational Medicine, National Chung Hsing University, 
      Taichung, Taiwan.
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
AD  - Master Program for Health Administration, Department of Industrial Engineering 
      and Enterprise Information, Tunghai University, Taichung, Taiwan.
AD  - Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and 
      Management, Miaoli, Taiwan.
FAU - Fu, Pin-Kuei
AU  - Fu PK
AD  - Department of Critical Care Medicine, Taichung Veterans General Hospital, 
      Taichung, Taiwan.
AD  - College of Human Science and Social Innovation, Hungkuang University, Taichung, 
      Taiwan.
AD  - Department of Computer Science, Tunghai University, Taichung, Taiwan.
FAU - Chan, Ming-Cheng
AU  - Chan MC
AD  - College of Medicine, National Chung Hsing University, Taichung, Taiwan.
AD  - Division of Critical Care and Respiratory Therapy, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Chin, Chun-Shih
AU  - Chin CS
AD  - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
FAU - Huang, Wen-Nan
AU  - Huang WN
AD  - College of Medicine, National Chung Hsing University, Taichung, Taiwan.
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Lai, Kuo-Lung
AU  - Lai KL
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Wang, Jiun-Long
AU  - Wang JL
AD  - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Ph.D. Program in Translational Medicine, National Chung Hsing University, 
      Taichung, Taiwan.
AD  - Agricultural Biotechnology Research Center, National Chung Hsing University, 
      Taichung, Taiwan.
AD  - Department of Life Sciences, National Chung Hsing University, Taichung, Taiwan.
FAU - Hung, Wei-Ting
AU  - Hung WT
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Wu, Yi-Da
AU  - Wu YD
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Hsieh, Chia-Wei
AU  - Hsieh CW
AD  - Ph.D. Program in Translational Medicine, National Chung Hsing University, 
      Taichung, Taiwan.
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
FAU - Wu, Ming-Feng
AU  - Wu MF
AD  - Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - Department of Medical Laboratory Science and Biotechnology, Central Taiwan 
      University of Science and Technology, Taichung, Taiwan.
FAU - Chen, Yi-Hsing
AU  - Chen YH
AD  - Division of Allergy, Immunology and Rheumatology, Department of Internal 
      Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
AD  - School of Medicine, National Yang Ming Chia Tung University, Taipei, Taiwan.
FAU - Hsu, Jeng-Yuan
AU  - Hsu JY
AD  - Division of Clinical Research, Department of Medical Research, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
AD  - School of Physical Therapy, Chung-Shan Medical University, Taichung, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20220103
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8761618
OTO - NOTNLM
OT  - anti-IgE
OT  - asthma
OT  - minimal clinically important difference (MCID)
OT  - omalizumab
OT  - predictor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/01/21 06:00
MHDA- 2022/01/21 06:01
PMCR- 2022/01/03
CRDT- 2022/01/20 06:06
PHST- 2021/08/21 00:00 [received]
PHST- 2021/12/01 00:00 [accepted]
PHST- 2022/01/20 06:06 [entrez]
PHST- 2022/01/21 06:00 [pubmed]
PHST- 2022/01/21 06:01 [medline]
PHST- 2022/01/03 00:00 [pmc-release]
AID - 10.3389/fmed.2021.762318 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Jan 3;8:762318. doi: 10.3389/fmed.2021.762318. 
      eCollection 2021.